Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer.

ABSTRACT: Despite substantial effort, there remains a lack of biomarker-based, clinically relevant testing for the accurate, non-invasive diagnostic or prognostic profiling of epithelial ovarian cancers (EOC). Our previous work demonstrated that whilst the inflammatory marker C-X-C motif chemokine ligand 10 (CXCL10) has prognostic relevance in ovarian cancer, its use is complicated by the presence of multiple, N-terminally modified variants, mediated by several enzymes including Dipeptidyl Peptidase 4 (DPP4). In this study, we provide the first evidence for the "Active Ratio Test" (ART) as a novel method to measure biologically relevant CXCL10 proteoforms in clinical samples. In a cohort of 275 patients, ART accurately differentiated patients with malignant EOCs from those with benign gynaecological

SUBMITTER: Kang SW 

PROVIDER: S-EPMC8230042 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature